8-K: NRC Health Reports Q2 2026 Financial Results

NRC Health announced its second quarter 2026 financial and operating results, highlighting an 11% year-over-year increase in Total Recurring Contract Value (TRCV) to $151.9 million.

Summary

• NRC Health reported its financial results for the second quarter ended June 30, 2026.
• Total Recurring Contract Value (TRCV) increased by 11% year-over-year to $151.9 million.
• Total revenue for the quarter was $35.4 million, a 4% increase from the prior year.
• The company reported a GAAP net loss of ($3.3) million, or ($0.15) per diluted share.
• Adjusted Net Income was $6.9 million, or $0.31 per diluted share.
• Adjusted EBITDA was $9.4 million, representing 27% of revenue.
• Net cash flow from operating activities was $1.4 million, and free cash flow was $0.1 million.
• A quarterly cash dividend of $0.16 per share was declared, payable on October 9, 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive report, with strong TRCV growth and revenue increases, though tempered by a GAAP net loss and significant adjustments.

Positives

• Total Recurring Contract Value (TRCV) increased 11% year-over-year to $151.9 million, indicating strong future revenue potential.
• Revenue grew 4% year-over-year to $35.4 million.
• Strong bookings performance for The Governance Institute, the best in seven years.
• Adjusted Net Income was $6.9 million, representing 19% of revenue.
• Adjusted EBITDA was $9.4 million, representing 27% of revenue.
• Net cash flow from operating activities was $1.4 million.
• The company declared a quarterly cash dividend of $0.16 per share.

Negatives

• Reported a GAAP net loss of ($3.3) million for the quarter.
• GAAP net loss per fully diluted share was ($0.15).
• Free cash flow was $0.1 million, reflecting significant cash payments related to adjustment items.
• Total operating expenses increased to $38.6 million from $32.5 million in the prior year's quarter.

Risks

• Actual results or events may differ from forward-looking statements due to significant risks and uncertainties.
• Risks and uncertainties are detailed in the Company's Annual Report on Form 10-K for the year ended December 31, 2025, and other SEC filings.

Future Outlook

The company is well-positioned for a strong second half of 2026, driven by continued commercialization of product innovations and strong bookings performance.

Management Comments

• "Our second quarter was a success on many fronts, including double-digit TRCV growth over the prior year, strong go-to-market and solutions delivery execution, continued commercialization of our product innovations, and the strongest bookings performance for The Governance Institute in seven years, positioning us well for a strong second half of 2026."
• "As healthcare organizations increasingly seek partners who can help improve experience outcomes, strengthen governance, and build enduring brand value, we believe NRC Health is uniquely differentiated through our three connected strengths: delivering continuous consumer and patient insights, providing trusted partnership and strategic engagement with healthcare leaders, and enabling actions that lead to improved outcomes."

Industry Context

StockSavvy.ai notes that NRC Health's focus on healthcare experience improvement aligns with a growing industry trend where patient and consumer satisfaction are becoming critical differentiators and drivers of success for healthcare organizations.

Comparison to Industry Standards

• No specific industry benchmarks or comparable company results were provided in the filing.

Stakeholder Impact

• Shareholders: Will receive a quarterly cash dividend of $0.16 per share.
• Healthcare Organizations (Customers): Benefit from NRC Health's solutions to improve patient and consumer experience, governance, and brand value.
• Employees: Potential impact from restructuring costs mentioned in management transition costs.

Next Steps

• Host a conference call to discuss financial results on Tuesday, July 28, 2026, at 4:30 p.m. ET.
• Shareholders to receive dividend on October 9, 2026.

Key Dates

Recommendation

The company shows positive trends in recurring contract value and revenue, alongside a declared dividend. However, the GAAP net loss and the reliance on adjusted metrics suggest a cautious approach. A 'hold' recommendation is appropriate pending further clarity on the sustainability of adjusted profitability and the impact of management transition costs.

Keywords

Healthcare Experience Improvement, Total Recurring Contract Value, Second Quarter Results, Financial Performance, Healthcare Solutions, Patient Insights, Corporate Governance, Earnings Release